VJHemOnc is committed to improving our service to you

MPN Advances Day 2019 | What to look out for at ASH 2019: MPNs

VJHemOnc is committed to improving our service to you

Mary Frances McMullin

Mary Frances McMullin, MD, Queen’s University Belfast, Belfast, UK, highlights the ropeginterferon alfa-2b treatment for polycythemia vera (PV) clinical trial data she is expecting to be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition 2019. Prof. McMullin discusses the myeloproliferative neoplasms (MPNs) education session on diagnostic workflow for hereditary erythrocytosis and thrombocytosis. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter